This article is more than 5 years old. Information may no longer be current.

QLT reports third-quarter net income of $81.5 million

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

QLT reported a net income of $81.5 million for the third quarter, according to a press release.

The company reported $94.1 million in third-quarter income from discontinued operations resulting from the sale of Visudyne (verteporfin for injection) in September. In the third quarter of 2011, the company reported a net loss of $9.1 million.

QLT’s operating loss for the third quarter of 2012 was $19.9 million, compared with $10.1 million in the same period last year.

QLT’s third-quarter research and development expenses for the synthetic retinoid program were $5.6 million, down from $6.1 million in the same quarter last year.

The company reported a $54.9 million net income for the first three quarters of 2012, partially related to the Visudyne sale, compared to a net loss of $23.8 million for the first three quarters of 2011.